Please login to the form below
GSK's Q3 sales grow 3 per cent
GlaxoSmithKline recorded a growth in sales of 3 per cent in its financial results for the third quarter of 2011, as net income remained level
GlaxoSmithKline (GSK) has recorded a growth in sales of 3 per cent in its financial results for the third quarter of 2011.
The UK-based pharmaceutical company had a turnover of $7.10bn for the period compared to $6.81bn in 2010.
Net profit for GSK remained stationery at $1.49bn, however, as costs related to selling and administration rose.
Vaccines were a particularly strong area of growth for GSK, with revenue in the division increasing by 21 per cent. This was mainly related to sales of Cervarix as part of Japan's national HPV programme.
Total turnover grew 34 per cent in Japan during the quarter, with the strong performance of Avodart following its recent launch also contributing to strong sales in the region.
Emerging markets also saw increased revenue, growing by 11 per cent, helping the company overcome a drop in sales of 5 per cent in Europe and 1 per cent in the US.
Share
Related Hub content
Your search did not contain any words. Please try again.
Featured jobs
- Senior Brand Manager - Harlow
- Competitive
- Sales Manager - Media Publishing – Cheshire
- 25,000 to 35,000 per annum
- UK Marketing Director
- 80,000 to 100,000 per annum
- Group Account Director –Healthcare Advertising
- Neg
Subscribe to our email news alerts
- Achieving an aligned business intelligence capability - fact or fiction?
- Former Google chief launches online cancer forum
- Global biosimilars market to reach $2.45bn in 2013
- Value-based pricing "not in patient interest"
- Bringing trial data out of the shadows
- Novartis gets FDA green light for new Ilaris indication
- David Nicholson to step down as head of England’s NHS
- Roche repeats cancer drugs warning as Avastin faces another NICE rejection
- Italian pharma market set for continued downturn
- Novartis wins third NICE recommendation for Lucentis
- Health editor at The Sun newspaper joins Ruder Finn
- Informational source shift: from marketing to medical
PMHub
Add my companySay Communications
Clarity of vision, insight and a thought-through strategic approach are our tools for delivering solutions that benefit our clients and ...
Latest intelligence
- How can pharma deliver returns on increased digital investment?
- Independent online professional networks work best as part of a multi-channel campaign ...
- The impact of Hollande's healthcare reforms in France
- A tougher environment for pharma, with market access and regulatory challenges...
- A guide to developing customer-centred, multichannel marketing
- Find out how a balanced approached to multichannel marketing could benefit your brand - the customer's agenda is just as important as Pharma's and needs to be listened to in ...
Quick links
